Brissot, Eolia Labopin, Myriam Moiseev, Ian Cornelissen, J. J. Meijer, Ellen Van Gorkom, Gwendolyn Rovira, Montserrat Ciceri, Fabio Griskevicius, Laimonas Blaise, Didier
...
Published in
Journal of Hematology & Oncology
BackgroundGraft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte globulin or anti-T-lymphocyte globulin (ATG) should be used for GVHD prophylaxis in patients undergoing matched-unrelated donor (MUD) ...
Zhou, Xiangxiang Zhan, Linquan Huang, Kai Wang, Xin
Published in
Journal of Hematology & Oncology
With covalently closed circular structures, circular RNAs (circRNAs) were once misinterpreted as by-products of mRNA splicing. Being abundant, stable, highly conserved, and tissue-specific, circRNAs are recently identified as a type of regulatory RNAs. CircRNAs bind to certain miRNAs or proteins to participate in gene transcription and translation....
Cortes, Jorge E. de Lima, Marcos Dombret, Hervé Estey, Elihu H. Giralt, Sergio A. Montesinos, Pau Röllig, Christoph Venditti, Adriano Wang, Eunice S.
Published in
Journal of Hematology & Oncology
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years old. GO treatment has been associated with an incre...
López de Andrés, Julia Griñán-Lisón, Carmen Jiménez, Gema Marchal, Juan Antonio
Published in
Journal of Hematology & Oncology
Cancer stem cells (CSCs) represent a tumor subpopulation responsible for tumor metastasis and resistance to chemo- and radiotherapy, ultimately leading to tumor relapse. As a consequence, the detection and eradication of this cell subpopulation represent a current challenge in oncology medicine. CSC phenotype is dependent on the tumor microenvironm...
Zubovic, Lorena Piazza, Silvano Tebaldi, Toma Cozzuto, Luca Palazzo, Giuliana Sidarovich, Viktoryia De Sanctis, Veronica Bertorelli, Roberto Lammens, Tim Hofmans, Mattias
...
Published in
Journal of Hematology & Oncology
Pediatric myelodysplastic syndrome (PMDS) is a very rare and still poorly characterized disorder. In this work, we identified novel potential targets of PMDS by determining genes with aberrant expression, which can be correlated with PMDS pathogenesis. We identified 291 differentially expressed genes (DEGs) in PMDS patients, comprising genes involv...
Govindarajan, Meinusha Wohlmuth, Christoph Waas, Matthew Bernardini, Marcus Q. Kislinger, Thomas
Published in
Journal of Hematology & Oncology
High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succum...
Yilmaz, Musa Alfayez, Mansour DiNardo, Courtney D. Borthakur, Gautam Kadia, Tapan M. Konopleva, Marina Y. Loghavi, Sanam Kanagal-Shamanna, Rashmi Patel, Keyur P. Jabbour, Elias J.
...
Published in
Journal of Hematology & Oncology
BackgroundSecond-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i exposure remain poorly defined.MethodsWe retrospectivel...
García-Suárez, Julio de la Cruz, Javier Cedillo, Ángel Llamas, Pilar Duarte, Rafael Jiménez-Yuste, Víctor Hernández-Rivas, José Ángel Gil-Manso, Rodrigo Kwon, Mi Sánchez-Godoy, Pedro
...
Published in
Journal of Hematology & Oncology
BackgroundPatients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on...
Qian, Yunzhen Gong, Yitao Fan, Zhiyao Luo, Guopei Huang, Qiuyi Deng, Shengming Cheng, He Jin, Kaizhou Ni, Quanxing Yu, Xianjun
...
Published in
Journal of Hematology & Oncology
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using next-generation sequencing (NGS), these aberrant alterations can be identified and used to develop strategies that will selectively kill cancer...
Lancman, Guido Mascarenhas, John Bar-Natan, Michal
Published in
Journal of Hematology & Oncology
SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was initially...
